The role of Iron, omega-3 fatty acids, and vitamins in heart failure

Current Treatment Options in Cardiovascular Medicine

Volumn 14, Issue 4, 2012, Pages 328-341

  Silverberg, Donald S ^a   Schwartz, Doron ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Anemia; Erythropoietin; Folic acid; Heart failure; Homocysteine; Iron deficiency; Omega 3; Renal failure; Thiamine; Vitamin B6; Vitamin D; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ANTIANEMIC AGENT; CYANOCOBALAMIN; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERRLE; FERUMOXYTOL; FISH OIL; FOLIC ACID; HOMOCYSTEINE; ICOSAPENTAENOIC ACID; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OMEGA 3 FATTY ACID; PYRIDOXINE; THIAMINE; UNCLASSIFIED DRUG; VITAMIN; VITAMIN D;

ADVERSE OUTCOME; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG SAFETY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON THERAPY; PATIENT SAFETY; QUALITY OF LIFE; REVIEW; STROKE; THERAPY EFFECT; THIAMINE DEFICIENCY; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 84865694238     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-012-0188-3     Document Type: Review

References (98)

1. Chen J, Normand S-L T, Wang Y, Krumholz HN. National and regional trends in heart failure hospitalizations and mortality rates for medicare beneficiaries 1998-2008. JAMA. 2011;306:1669-78.
2. Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: A randomized controlled trial. JAMA. 2005;293:1338-47. (Pubitemid 40381486)
3. Marchioli R, Levantesi G, Macchia A, et al. GISSIPrevenzione investigators. Vitamin E increases the risk of developing heart failure after myocardial infarction: Results from the GISSI-Prevenzione trial. J Cardiovasc Med. 2006;7:347-50. (Pubitemid 44145638)
4. Miller 3rd ER, Pastor-Barriuso R, Dalal D, et al. Metaanalysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37-46.
5. Clarke R, Halsey J, Lewington S, et al. B-vitamin treatment trialists' collaboration effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med. 2010;170:1622-31.
6. Clarke R, Halsey J, Bennett D, Lewington S. J Inherit Metab Dis 2011, 34:83-91
7. Homocysteine and vascular disease: Review of published results of the homocysteine-lowering trials. J Inherit Metab Dis. 2011;34:83-91.
8. Abraham JM, Cho L. The homocysteine hypothesis: Still relevant to the prevention and treatment of cardiovascular disease? Cleve Clin J Med. 2010;77:911-8.
9. Sundström J, Sullivan L, Selhub J, et al. Relations of plasma homocysteine to left ventricular structure and function: The Framingham Heart Study. Eur Heart J. 2004;25:523-3.
10. Washio T, Nomoto K, Watanabe I, et al. Relationship between plasma homocysteine levels and congestive heart failure in patients with acute myocardial infarction. A high plasma homocysteine level in acute MI is a risk factor and an independent predictor for the development of heart failure. Int Heart J. 2011;52:224-8.
11. Vasan RS, Beiser A, D'Agostino RB, et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA. 2003;289:1251-7. (Pubitemid 37432905)
12. Miller 3rd ER, Juraschek S, Pastor-Barriuso R, et al. Metaanalysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels. Am J Cardiol. 2010;106:517-27.
13. Martí-Carvajal AJ, Solà I, Lathyris D, Salanti G. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2009;7:CD006612.
14. Durga J, Bots ML, Schouten EG, et al. Effect of 3 years of folic acid supplementation on the progression of carotid intima-media thickness and carotid arterial stiffness in older adults. Am J Clin Nutr. 2011;93:941-9.
15. House AA, Eliasziw M, Cattran DC, et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: A randomized controlled trial. JAMA. 2010;303:1603-9.
16. Agarwal M, Phan A, Willix Jr R, Barber M, Schwarz ER. Is vitamin D deficiency associated with heart failure? A review of current evidence. J Cardiovasc Pharmacol Ther. 2011;16:354-63.
17. Meems LM, van der Harst P, van Gilst WH, de Boer RA. Vitamin D biology in heart failure: Molecular mechanisms and systematic review. Curr Drug Targets. 2011;12:29-41.
18. Witham MD. Vitamin D in chronic heart failure. Curr Heart Fail Rep. 2011;8:123-30.
19. Schleithoff SS, Zittermann A, Tenderich G, et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: A doubleblind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83:754-9. (Pubitemid 44713136)
20. Witham MD, Crighton LJ, Gillespie ND, Struthers AD, McMurdo ME. The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: A randomized controlled trial. Circ Heart Fail. 2010;3:195-201.
21. Monk RD, Bushinsky DA. Making sense of the latest advice on vitamin D therapy. J Am Soc Nephrol. 2011;22:994-8.
22. Soukoulis V, Dihu JB, Sole M, et al. Micronutrient deficiencies an unmet need in heart failure. J Am Coll Cardiol. 2009;54:1660-73.
23. Sarma S, Gheorghiade M. Nutritional assessment and support of the patient with acute heart failure. Curr Opin Crit Care. 2010;16:413-8.
24. Lee JH, Jarreau T, Prasad A, et al. Nutritional assessment in heart failure patients. Congest Heart Fail. 2011;17:199-203.
25. Mozaffarian D, Wu JH. Omega-3 Fatty acids and cardiovascular disease: Effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58:2047-67. This paper summarizes all aspects of the role of omega-3 in cardiovascular diseases.
26. Nodari S, Triggiani M, Manerba A, Milesi G, Dei Cas L. Effects of supplementation with polyunsaturated fatty acids in patients with heart failure. Intern Emerg Med. 2011;6 Suppl 1:37-44.
27. Levantesi G, SillettaMG,Marchioli R. Uses and benefits of omega-3 ethyl esters in patients with cardiovascular disease. J Multidiscip Health. 2010;3:79-96.
28. Kromhout D, Yasuda S, Geleijnse JM, Shimokawa H. Fish oil and omega-3 fatty acids in cardiovascular disease: Do they really work? Eur Heart J. 2011 Sep 26. [Epub ahead of print].
29. Davidson MH, Kling D, Maki KC. Novel developments in omega-3 fatty acid-based strategies. Curr Opin Lipidol 2011 Oct 7. [Epub ahead of print].
30. Jarreau TK, Lee JH, Lavie CJ, Ventura HO. Should we start prescribing omega-3 polyunsaturated fatty acids in chronic heart failure? Curr Heart Fail Rep 2011, Nov 3. [Epub ahead of print].
31. Teng LL, Shao L, Zhao YT, et al. The beneficial effect of n-3 polyunsaturated fatty acids on doxorubicin-induced chronic heart failure in rats. J IntMedRes. 2010;38:940-8.
32. Chen J, Shearer GC, Chen Q, et al. Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts. Circulation. 2011;123:584-93.
33. Duda MK, O'Shea KM, Tintinu A, et al. Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. Cardiovasc Res. 2009;81:319-27.
34. Yamagishi K, Iso H, Date C, Japan Collaborative Cohort Study for Evaluation of Cancer Risk Study GroupFish, et al. omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women the JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk) Study. J Am Coll Cardiol. 2008;52:988-96.
35. Yamagishi K, Nettleton JA, Folsom AR, ARIC Study Investigators. Plasma fatty acid composition and incident heart failure in middle-aged adults: The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2008;156:965-74.
36. Belin RJ, Greenland P, Martin L, et al. Fish intake and the risk of incident heart failure: The women's health initiative. Circ Heart Fail. 2011;4:404-13.
37. Levitan EB, Wolk A, Mittleman MA. Fatty fish, marine omega-3 fatty acids and incidence of heart failure. Eur J Clin Nutr. 2010;64:587-94.
38. Mozaffarian D, Lemaitre RN, King IB, et al. Circulating long-chain {omega}-3 fatty acids and incidence of congestive heart failure in older adults: The cardiovascular health study: A cohort study. Ann Intern Med. 2011;155:160-70.
39. Dijkstra SC, Brouwer IA, van Rooij FJ, et al. Intake of very long chain n-3 fatty acids from fish and the incidence of heart failure: The Rotterdam Study. Eur J Heart Fail. 2009;11:922-8.
40. Rupp H, Rupp TP, Alter P, Maisch B. Inverse shift in serum polyunsaturated and monounsaturated fatty acids is associated with adverse dilatation of the heart. Heart. 2010;96:595-8.
41. GISSI-Preventione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354:447-55.
42. Marchioli R, Barzi F, Bomba E, GISSI-Prevenzione Investigators, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation. 2002;105:1897-903. (Pubitemid 34437615)
43. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090-8. (Pubitemid 46483662)
44. Macchia A, Levantesi G, Franzosi MG, et al. Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. Eur J Heart Fail. 2005;7:904-9. (Pubitemid 41125915)
45. Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1223-30.
46. Ghio S, Scelsi L, Latini R, GISSI-HF investigators, et al. Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: A substudy of GISSI-HF trial. Eur J Heart Fail. 2010;12:1345-53.
47. Nodari S, Triggiani M, Campia U, et al. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2011;57:870-9. This small double-blind placebo-controlled study showed a significant improvement in many aspects of heart failure.
48. Moertl D, Hammer A, Steiner S et al. Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: A double-blind, placebo-controlled, 3-arm study. Am Heart J. 2011;161:915.e1-9.
49. Zhao YT, Shao L, Teng LL, et al. Effects of n-3 polyunsaturated fatty acid therapy on plasma inflammatory markers and N-terminal pro-brain natriuretic peptide in elderly patients with chronic heart failure. J Int Med Res. 2009;37:1831-41.
50. Mehra MR, Lavie CJ, Ventura HO, Milani RV. Fish oils produce anti-inflammatory effects and improve body weight in severe heart failure. J Heart Lung Transplant. 2006;25:834-8. (Pubitemid 43963369)
51. Martínez-Quintana E, Rodríguez-González F, Torres-Fuentes E, López-Ríos L, Nieto-Lago V. Effect of omega-3 acids on clinical evolution, plasma inflammatory biomarkers and B-type natriuretic peptide levels in patients with coronary heart disease. Med Clin (Barc). 2011;136:574-7.
52. Nodari S, Metra M. Milesi G The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy. Cardiovasc Drugs Ther. 2009;23:5-15.
53. Finzi AA, Latini R, Barlera S, et al. Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: A substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) trial. Am Heart J. 2011;161:338-43.
54. Moertl D, Berger R, Hammer A, et al. Dose-dependent decrease of platelet activation and tissue factor by omega-3 polyunsaturated fatty acids in patients with advanced chronic heart failure. Thromb Haemost. 2011;106:457-65.
55. Cowie MR, Cure S, Bianic F, et al. Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: Results of Markov modelling in a UK setting. Eur J Heart Fail. 2011;13:681-9.
56. Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: A randomized controlled trial. JAMA. 2010;304:2363-72.
57. Harris WS. Expert opinion: Omega-3 fatty acids and bleeding-cause for concern? Am J Cardiol. 2007;99 (6A):44C-6C.
58. Salisbury AC, Harris WS, Amin AP, Reid KJ, O'Keefe Jr JH, Spertus JA. Relation between red blood cell omega-3 fatty acid index and bleeding during acute myocardial infarction. Am J Cardiol. 2011, Sep 23. [Epub ahead of print].
59. Goldberg RJ, Katz J. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain. 2007;129:210-23. (Pubitemid 46551386)
60. Galarraga B, Ho M, Youssef HM, et al. Cod liver oil (n-3 fatty acids) as an non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis. Rheumatology. 2008;47:665-9. (Pubitemid 351619210)
61. Tokuyama S, Nakamoto K. Unsaturated fatty acids and pain. Biol Pharm Bull. 2011;34:1174-48.
62. Maroon JC, Bost JW. Omega-3 fatty acids (fish oil) as an anti-inflammatory: An alternative to nonsteroidal anti-inflammatory drugs for discogenic pain. Surg Neurol. 2006;65:326-3.
63. Ko GD, Nowacki NB, Arseneau L, Eitel M, Hum A. Omega-3 fatty acids for neuropathic pain: Case series. Clin J Pain. 2010;26:168-72.
64. Tang WH, Samara MA. Polyunsaturated fatty acids in heart failure: Should we give more and give earlier? J Am Coll Cardiol. 2011;57:880-3.
65. Smith SC, Benjamin EJ, Bonow RO et al, Guideline From the American Heart Association and American College of With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update : A AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patient AHA/ACCF Guideline AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation. . Circulation published online November 3, 2011
66. Fonarow GC. Statins and n-3 fatty acid supplementation in heart failure. Lancet. 2008;372:1195-6.
67. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: An ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010;31:1872-80.
68. Parikh A, Natarajan S, Lipsitz SR, Katz SD. Iron deficiency in community-dwelling U.S. adults with selfreported heart failure in NHANES III: Prevalence and associations with anemia and inflammation. Circ Heart Fail 2011 Jun 24. [Epub ahead of print].
69. Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011;58:1241-5.
70. Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006;48:2485-9. (Pubitemid 44881220)
71. Maeder MT, Khammy O, dos Remedios C, Kaye DM. Myocardial and systemic iron depletion in heart failure implications for anemia accompanying heart failure. J Am Coll Cardiol. 2011;58:474-80.
72. Leszek P, Sochanowicz B, Szperl M, et al. Myocardial iron homeostasis in advanced chronic heart failure patients Int JCardiol. 2011 Sep 5. [Epub ahead of print]
73. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail. 2011;17:899-906.
74. Bolger AP, Bartlett FP, Penston HS, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006;48:1225-7. (Pubitemid 44345150)
75. Usmanov RI, Zueva EB, Silverberg DS, Shaked M. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol. 2008;21:236-42.
76. Gaber R, Kotb NA, Ghazy M, et al. Tissue doppler and strain rate imaging detect improvement of myocardial function in iron deficient patients with congestive heart failure after iron replacement therapy. Echocardiography. 2011 Nov 2. (Epub ahead of print)
77. Toblli JE, Lombraña A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-BNP in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50:1657-65. (Pubitemid 47562670)
78. Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: A randomized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008;51:103-12.
79. Anker SD, Comin Colet J, et al. FAIR-HF trial investigators ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436-48. This was a large, double-blind, placebo-controlled study of intravenous iron in heart failure showing a rapid and significant improvement in many parameters.
80. Palazzuoli A, Silverberg D, Iovine F et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J. 2006;152:1096.e9-15
81. Besarab A, Hörl WH, Silverberg D. Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome. Oncologist. 2009;14 Suppl 1:22-33.
82. González-Costello J, Comín-Colet J. Iron deficiency and anaemia in heart failure: Understanding the FAIR-HF trial. Eur J Heart Fail. 2010;12:1159-62.
83. van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC. Anemia and iron deficiency in heart failure: Mechanisms and therapeutic approaches. Nat Rev Cardiol. 2011;8:485-93.
84. Silverberg DS, Wexler D, Iaina A, Schwartz D. Correction of iron deficiency in the cardiorenal syndrome. Int J Nephrol. 2011;Apr 19 Epub 2011 84. Nemeth E. Iron regulation and erythropoiesis. Curr Opin Hematol. 2008;15:169-75.
85. Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta. 2009;1790:682-93.
86. Ponka P. Cellular iron metabolism. Kidney Int Suppl. 1999;69:S2-S11. (Pubitemid 29113577)
87. Naito Y, Tsujino T, Matsumoto M, et al. Adaptive response of the heart to long term anemia induced by iron deficiency. Am J Physiol Heart Circ Physiol. 2009;296:H585-96.
88. Dong F, Zhang X, Culver B, et al. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrosome C release: Involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci. 2005;109:277-86. (Pubitemid 41337132)
89. Rhodes CJ, Wharton J, Howard L et al. Iron deficiency in pulmonary arterial hypertension: A potential therapeutic target. Eur Respir J. 2011;May 20. [Epub ahead of print].
90. van der Meer P, Groenveld H, Januzzi Jr JL, van Veldhuisen DJ. Erythropoietin treatment in patients with Chronic Heart Failure: A meta-analysis. Heart. 2009;95:1309-14.
91. Ngo K, Kotecha D, Walters JA, et al. Erythropoiesisstimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev 2010;(1): CD007613.
92. Desai A, Lewis E, Solomon S, et al. Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: An updated, post-TREAT metaanalysis. Eur J Heart Fail. 2010;12:936-42.
93. Unger EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-stimulating agents: Time for a reevaluation. N Engl J Med. 2010;362:189-92.
94. Skali H, Parving HH, Parfrey PS et al on behalf of the TREAT Investigators. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with darbepoetin alfa: The Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) experience. Circulation 2011;Nov 21. [Epub ahead of print].
95. McMurray JJ, Anand IS, Diaz R, et al. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): A Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail. 2009;11:795-801.
96. Van Wyck DB, Roppolo M, Martinez CO, et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with non-dialysis dependent CKD. Kidney Int. 2005;68:2846-56. (Pubitemid 43251032)
97. Rozen-Zvi B, Gafter-Gvili A, Paul M, et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: Systematic review and meta-analysis. Am J Kidney Dis. 2008;52:897-906.
98. Macdougall IC. Iron supplementation in the nondialysis chronic kidney disease (ND-CKD) patient: Oral or intravenous? Curr Med Res Opin. 2010;26:473-8.